A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (NCT04965493)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.
Who can join: Review the eligibility criteria below.
Location: Ironwood Physicians, Ironwood Cancer and Research Centers — Chandler, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (176 Sites)
Showing the first 25 of 176 sites.
- Ironwood Physicians, Ironwood Cancer and Research Centers — Chandler, Arizona
- Mayo Clinic Hospital — Phoenix, Arizona
- University of California Irvine Medical Center — Orange, California
- Scripps Mercy Hospital — San Diego, California
- Providence Medical Foundation — Santa Rosa, California
- Stamford Hospital — Stamford, Connecticut
- Florida Cancer Specialists — Fort Myers, Florida
- Cancer Specialists of North Florida -St Augustine — Saint Augustine, Florida
- Florida Cancer Specialists East — West Palm Beach, Florida
- Mission Cancer and Blood — Des Moines, Iowa
- Pikeville Medical Center, Inc. — Pikeville, Kentucky
- American Oncology Partners of Maryland, PA — Bethesda, Maryland
- Dana-Farber Cancer Institute — Boston, Massachusetts
- St. Joseph Mercy Hospital — Ann Arbor, Michigan
- University of Michigan — Ann Arbor, Michigan
- Mayo Clinic — Rochester, Minnesota
- Research Medical Center — Kansas City, Missouri
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
- The Mount Sinai Hospital — New York, New York
- Columbia University Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Levine Cancer Institute — Charlotte, North Carolina
- Novant Cancer Institute Charlotte — Charlotte, North Carolina
- Duke University Medical Center — Durham, North Carolina
- Regional Medical Oncology Center — Wilson, North Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Lymphocytic Leukemia
- Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia — Houston, Texas
- Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia — Rochester, Minnesota
- A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) — Anchorage, Alaska
- Economic Analysis of Alliance A041202 CLL Study — Calgary, Alberta
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL — Chandler, Arizona
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) — Phoenix, Arizona
Explore by condition: All Chronic Lymphocytic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.